89
Views
0
CrossRef citations to date
0
Altmetric
Research Article

How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?

Pages 3-14 | Published online: 10 Jul 2009

  • Kasarkis EJ, Winslow M. When did Lou Gehrig's personal illness begin? Neurology 1989; 39:1243-1245.
  • Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial ALS. Ann Neurol 1996; 39:147-157.
  • World Federation of Neurology Research Croup on Neuromuscular Disease Subcommittee on Motor Neuron Disease. Airlie House Guidelines. Therapeutic Trials in Amyotrophic Lateral Sclerosis. J Neurol Sci 1995; 129(Suppl): 1-10.
  • Bromberg MB, Brooks BR. Issues in clinical trial design II: Selection of end point measures. Neurology 1996; 47(Suppl2):S100-S102.
  • Brooks BR. Natural history of ALS: Symptoms, strength, pulmonary function and disability. Neurology 1996; 47(Suppl2):S71-S82.
  • Brooks BR. Amyotrophic lateral sclerosis clinimetric scales guidelines for administration and scoring. In: Hemdon RM, ed. Handbook of clinical neurologic rating scales. Demos Vermande. 1997 New York, NY.
  • Fleming TR, DeMets DL Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605-613.
  • The ALS CNTF Treatment Study (ACTS) Phase I-II Study Croup. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Arch Neurol 1996; 53:141-147.
  • McGuire D, Garrison L, Armon C, et al and the SSNJV/CNTF ALS Study Group. Relationship of Tufts Quantitative Neuromuscular Examination (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of amyotrophic lateral sclerosis (ALS). Neurology 1996; 47:1442-1444.
  • Armon C, Ponraj E. Comparing composite scores based on maximal voluntary isometric contraction (MVIC) and on semi-quantitative manual motor testing (SQMMT) in measuring limb strength in patients with amyotrophic lateral sclerosis (ALS). Neurology 1996; 47:1586-1587.
  • Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995; 129(Suppl): 19-26.
  • Kleopa KA, Neal B, Sherman M, Heiman-Patterson T. Bipap prolongs survival in patients with ALS. 9th International Symposium on ALS/MND. 1998. Munich, Germany.
  • Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopie gastrostomy and enterai nutrition in amyotrophic lateral sclerosis. J Neurol 1995; 242: 695-698.
  • Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1998; 38: 405-408.
  • The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehabil 1996; 77: 1251-1255.
  • Hoagland RI, Mendoza PT, Armon C, et al. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Muscle Nerve 1997; 20: 691-695.
  • Mayo Clinic. Clinical examinations in neurology. 5th edn. Philadelphia: WB Saunders, 1981:131.
  • Dyck PJ, Sherman WR, Halcher LM, et al. Human diabetic endoneurial sorbitol fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
  • Windebank AL, Litchy WJ, Daube JR, Iverson, RA. Lack of progression of neurologie deficit in survivors of paralytic polio: a 5-year prospective population-based study. Neurology 1996; 46: 80-84.
  • Appel V, Stewart SS, Smith C, Appel SH. A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 1987; 22:328-333.
  • Haverkamp LJ, Appel V. Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Brain 1995; 118:707-719.
  • Fahn S, Elton R. Unified Parkinson's Disease rating scale. In: Fahn S, Marsden C, eds. Recent developments in Parkinson's disease. New York, NY: Macmillan, 1987:153-163.
  • Hillel AD, Miller RM, Yorkston K, McDonald E, Morris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiol 1989; 8: 142-150.
  • Third Symposium on Parkinson's Disease, held at the Royal College of Surgeons of Edinburgh, May 20-22, 1968. Edinburgh: Livingstone, 1969.
  • Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86.1 Neurol Neurosurg Psychiatry 1990; 53: 16-22.
  • Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. MD State Med 11965; 14: 61-65.
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.
  • Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334:835-840.
  • Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: (3)(Suppl):S217-S231.
  • Dodson WE, Trimble MR. Epilogue: Quality of life in epilepsy. In: Trimble MR, Dodson WE, eds. Epilepsy and quality of life. New York: Raven Press 1994:259-265.
  • Damiano AM. The Sickness Impact Profile. Quality of life and pharmacoeconomics in clinical trials. 2nd edn. Spiker B, ed. Philadelphia, PA: Lippincott-Raven, 1996.
  • Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 1996; 37: 577-582.
  • McGuire D, Garrison L, Armon C, et al. "Mini-SIP" quality of life indices correlate strongly with isometric muscular strength in measuring progression of ALS. 7th International Symposium on ALS/MND, 11-13 November 1996, Chicago, IL MND Association, Northampton, UK.
  • Bensimon G, Lacomblez L, Meininger V, for the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-591.
  • Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.
  • Lacomblez L, Bensimon B, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. Neurology 1996; 47(Suppl 4): S242-S250.
  • Medical Economics Co Inc. 1997 Physician's Desk Reference. Motivate, NJ: Medical Economics Co, 1997:2198-2201.
  • Lange DI, Felice KI, Grewal MI, et al. A double-blind, placebo-controlled, therapeutic trial to assess the efficacy of recombinant human insulin-like growth hormone (rhICF-1). In: The treatment of amyotrophic lateral sclerosis: a multicenter, double-blind, placebo-controlled clinical study. 6th International Symposium on ALS/MND, Dublin, October, 1995. MND Association, Northampton, UK.
  • Borasio CD, Leigh PN, Robberecht W, and the European ALS/ICF-1 Study Croup. The European trial of insulin-like growth factor l in ALS: an update. 7th International Symposium on ALS/MND, Chicago, IL, November, 1996. MND Association, Northampton, UK.
  • Leigh N, and the North American and European ALS/ICF-I Study Croups. The treatment of ALS with recombinant human insulin-like growth factor I (rhICF-I): pooled analysis of two clinical trials. Neurology 1997; 48: A217-218.
  • Miller RC, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47:1383-1388.
  • Neville HE, Brinkmann I, Murphy J, Miller RC, Moore D and WALS Study Croup. A comparison of two quantitative muscle strength measuring methods in the analysis of the ALS gabapentin trial data. 7th International Symposium on ALS/MND, Chicago, IL. November, 1996. MND Association, Northampton, UK.
  • ACTS CNFT Treatment Croup. A double-blind, placebo-controlled, clinical trial of subcutaneous recombinant human ciliary neurotrophic factor in ALS. Neurology 1996; 46: 1244-1249.
  • Miller RC, Petajan J, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256-260.
  • Bradley WG, for the BDNF Phase III Study Croup: A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Croup (Phase III). Neurology 1999; 52: 1427-1433.
  • Bradley WC and The BDNF Study Croup. Subcutaneous administration of recombinant brain-derived neurotrophic factor (r-metHuBDNF) in patients with amyotrophic lateral sclerosis. 6th International Symposium on ALS/MND, Dublin, October, 1995. MND Association, Northampton, UK.
  • Bryan WW, McIntire D, Camperiengo L, et al. Factors influencing the use of the riluzole by ALS patients. 8th International symposium on ALS/MND, Glasgow, 3-5 November 1997. MND Association, Northampton, UK.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.